自2007年2月起，Cambrex  Bioproducts作为瑞士lonza公司部下，还是原有的科研队伍及专业人员。将以同样的产品品质、同样的服务质量继续服务于广大用户！

 美国Cambrex成立于1981年，是全球人类健康与生物科学产品最主要的供应商，同时还是饲料添加剂的生产商和动物健康/农业市场的媒介以及优质化学试剂的制造商。主要有细胞株、培养基、分子生物学产品、内毒素检测试剂等.

美国Cambrex（BioWhittaker）公司作为美国最早的人体和动物细胞培养基的提供者，进入生物医药已有50年历史。其细胞培养产品主要有细胞培养基和生长的普通培养基，无血清、无蛋白培养基，特殊细胞的专用培养基，培养用的血清、生长因子、试剂等。这些产品主要用在生物技术研究和生物制药行业，如在药物，癌症治疗，干细胞治疗，遗传治疗，组织修复和移植等方面都有应用。另外在临床症断实验室，对有病历的样品进行病毒分离和鉴定方面也有应用。

最近随着人体和动物正常细胞体系的最大供应商美国Clonetics公司和世界顶级琼脂糖、凝胶生产者BMA（前FMC）公司的加盟。使Cambrex公司进入到细胞、细胞株供应培养和分子生物学领域。

Cambrex（BioWhittaker）公司鲎试剂内毒素检测产品被用在医药和医学领域，作为质量控制程序的一部分用来确保血管注射剂药物和医学仪器内毒素含量对人体的安全性。鲎试剂内毒素检测比给动物注射进行检测要更快，更精确，更经济实惠。

Cambrex is a leading supplier of products and services for the Life Sciences industry. We have built comprehensive technology platforms for use in small molecule API and advanced pharmaceutical intermediate synthesis, including enhanced drug delivery. Cambrex has extensive experience developing process to manufacture drug substances for clients use in tox. studies, clinical studies and commercial supply - from grams to tons. Our broad range of services include route selection, process & analytical development, process optimization & scale-up, safety assessments, and product formulation, in addition to an extensive list of generic APIs. Cambrex’s offerings include Controlled Substances, High Potency/Cytotoxics, Highly Energetic Chemistries, Polymeric Drug Delivery, Biocatalysis/Biotransformation, Chiral Synthesis, Hydrogenation, and Nitrations.

 

We have R&D and cGMP manufacturing facilities in the US and Europe, an excellent regulatory compliance record, and a strong expertise in various chemical technologies.  We are committed to operating  our facilities with the highest standards for regulatory, environmental, health, safety, and security guidelines.  We have also adopted the Lean Six Sigma (LSS) Process to consistently deliver efficient, high quality, and cost competitive products with less time-to-market for our clients. 

 

Our focus and goal is to provide solutions to large and small pharmaceutical companies with both established and emerging drug pipelines.